Compare CVS Health Corp (CVS) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Goldman Sachs Group Inc — how do they compare? CVS Health Corp trades at $86.3 (market cap $112.49B), while Goldman Sachs Group Inc trades at $888 (market cap $258.33B). The key difference: Goldman Sachs Group Inc is far larger — about 2.3× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Goldman Sachs Group Inc for 101 Days on average.
| CVS | GS | |
|---|---|---|
Market Cap | $112.49B | $258.33B |
Volume | 8,467,392 | 2,388,334 |
Sector | Health | Financials |
52-Week High | $110.60 | $1.15K |
52-Week Low | $70.08 | $744.60 |
Typical Hold Time | 83 Days | 101 Days |
Enterprise Value | $174.83B | $816.34B |
Dividend Yield | 3.02% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Goldman Sachs (GS) trades at $882.59, down 1.63% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $20.98 versus $14.47 expected. Revenue growth accelerated to $58.28B in 2025 with net income margin improving to 31.68%. Recent news highlights the company's focus on expanding to a $70B revenue base and AI initiatives.
The outlook remains positive with analyst consensus target of $1,130 representing 28% upside potential. Key risks include volatile cash flows with negative operating cash of -$45.15B in 2025 and potential FICC business softness. The current valuation at P/E of 13.7 appears attractive relative to earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
